Lidoflazine Explained

Verifiedfields:	changed
Watchedfields:	changed
Verifiedrevid:	447611733
Iupac Name:	2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
Cas Number:	3416-26-0
Atc Prefix:	C08
Atc Suffix:	EX01
Pubchem:	3926
Unii:	J4ZHN3HBTE
Kegg:	D04733
Chemspiderid:	3789
C:	30
H:	35
F:	2
N:	3
O:	1
Melting Point:	159
Melting High:	161
Solubility:	Almost insoluble in water(<0.01%); Very soluble in chloroform(>50%);
Smiles:	CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
Stdinchi:	1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)
Stdinchikey:	ZBIAKUMOEKILTF-UHFFFAOYSA-N

Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.^[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.

Physical properties

Solubility at room temperature

Extracted from

Solvent	0.01N		0.1N
		%	pH	%	pH
Hydrochloric Acid	0.4	3.0	0.7	1.9
Tartaric Acid	0.3	3.1	1.0	2.5
Citric Acid	0.3	3.1	0.5	2.5
Lactic Acid	0.2	3.4	0.7	2.9
Acetic Acid	0.1	3.5	0.4	3.8

Further reading

• Schaper WK, Xhonneux R, Jageneau AH . Stimulation of the coronary collateral circulation by lidoflazine (R 7904) . Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie . 252 . 1 . 1–8 . November 1965 . 4222721 . 10.1007/bf00246424 . 31959581 .

^[2]

Notes and References

1. Schaper WK, Xhoneux R, Jageneau AH, Janssen PA . The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator . The Journal of Pharmacology and Experimental Therapeutics . 152 . 2 . 265–274 . May 1966 . 5944369 .
2. Zhou PZ, Babcock J, Liu LQ, Li M, Gao ZB . Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules . Acta Pharmacologica Sinica . 32 . 6 . 781–788 . June 2011 . 21623390 . 4085723 . 10.1038/aps.2011.70 .